Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR
This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
- This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
- Myeloid will also share information on its portfolio of immune cell programming CARs.
- "We are thrilled to continue driving this first in vivo mRNA CAR program forward," said Chief Executive Officer Daniel Getts, Ph.D. "Myeloid is at the forefront of in vivo immune cell programming.
- To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.